Recordati Industria Chimica e Farmaceutica S.p.A. reported its results for the second quarter of 2026, according to the company's earnings call presentation.
17 %
Revenue growth in rare diseases for Recordati in Q2 2026.
Rare diseases fueled 17% growth for Recordati during the quarter, as stated in the presentation.
The company also reported that margins expanded in the first half of 2026.